Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) were up 0.9% on Tuesday. The stock traded as high as $39.2550 and last traded at $39.1440. 155 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 3,047 shares. The stock had previously closed at $38.81.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on CZMWY shares. Zacks Research raised Carl Zeiss Meditec from a "strong sell" rating to a "hold" rating in a report on Tuesday, October 6th. Morgan Stanley initiated coverage on Carl Zeiss Meditec in a research note on Wednesday, September 2nd. They issued an "underweight" rating on the stock. The Goldman Sachs Group cut Carl Zeiss Meditec from a "hold" rating to a "sell" rating in a research report on Monday, October 5th. Finally, UBS Group lowered Carl Zeiss Meditec from a "neutral" rating to a "sell" rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Carl Zeiss Meditec presently has an average rating of "Strong Sell".
Read Our Latest Research Report on CZMWY
Carl Zeiss Meditec Stock Up 0.9%
The business's fifty day moving average is $36.47 and its two-hundred day moving average is $32.95.
About Carl Zeiss Meditec
(
Get Free Report)
Carl Zeiss Meditec AG is a medical technology company headquartered in Jena, Germany, and part of the ZEISS Group. The company develops, manufactures and distributes equipment and solutions for ophthalmology and microsurgery, serving hospitals, clinics and medical professionals worldwide.
Its ophthalmic portfolio includes diagnostic systems for examining the eye, equipment for cataract and refractive surgery, surgical lasers, intraocular lenses and other related products. The company also supplies surgical microscopes, visualization systems and digital technologies used in neurosurgery, spine surgery, ear, nose and throat procedures, and other microsurgical specialties.
Carl Zeiss Meditec was established in 2002 through the combination of the ophthalmic activities of Carl Zeiss and Asclepion-Meditec.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Carl Zeiss Meditec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carl Zeiss Meditec wasn't on the list.
While Carl Zeiss Meditec currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
